This is a working overview of rodent models, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
However, there have also been pleas to take a more nuanced approach to judging the distribution skewness of the impact factor. Ludo Waltman and Vincent Antonio Traag, in their 2021 paper, ran numerous simulations and concluded that "statistical objections against the use of the IF at the level of individual articles are not convincing", and that "the IF may be a more accurate indicator of the value of an article than the number of citations of the article".
==== First-pass effect and differences from other routes ==== The first-pass effect that occurs with oral estradiol results in unusually high levels of estrone and estrogen conjugates in the circulation as well as of estradiol in the liver. These unique properties of oral estradiol result in a number of pharmacological differences relative to the other routes of administration of estradiol. The high levels of estrone and estrogen conjugates that occur with oral estradiol raise the question of the pharmacodynamic significance of these metabolites. In contrast to estradiol however, estrone has very low activity as an estrogen. The affinities of estrone for the human ERs and its estrogenic activity have been reported to be approximately 3 to 4% of those of estradiol. In addition, unlike estradiol and estriol, estrone is not accumulated in target tissues. Because estrone can be transformed into estradiol, most of its activity in vivo is actually due to conversion into estradiol. In accordance, doses of oral and transdermal estradiol that achieve similar levels of estradiol have been found, in spite of markedly elevated levels of estrone with oral estradiol but not with transdermal estradiol, to possess equivalent and non-significantly different potency in terms of clinical measures including suppression of LH and FSH levels, inhibition of bone resorption, and relief of menopausal symptoms such as hot flashes. In addition, estradiol levels were found to correlate with these effects, while estrone levels did not.
When the PSOE took office the Spanish economy was in full expansion. One of the factors that had made this possible was the arrival of several million emigrants from Latin America, the Maghreb and Eastern Europe. But part of them were "undocumented" migrants so the government decided to proceed with a massive "regularization" throughout 2005 that affected about 700 000 people who obtained a residence permit by presenting a contract of employment. The PP accused the government of provoking a "call effect" of new emigrants. The integration of the four million emigrants who had arrived in Spain in the last 10 years – so that foreigners now accounted for almost 10% of the population – posed an enormous challenge for Spanish society. The main "engine" of economic growth was being the construction sector, driven by increased demand. However, much of it was the result of a speculative movement around the "brick" as many people did not buy the homes to inhabit them but to place their savings hoping to sell them later at a higher price. This was how the "Spanish property bubble" was fed. But in the summer of 2007, the outbreak of the subprime mortgage crisis in the United States had an immediate repercussion in Europe and especially in Spain, where housing prices stopped rising, the construction sector came to a standstill and this dragged down the economy as a whole which began to grow at a slower pace with the consequent increase in unemployment.
=== Patient perceptions === A study conducted in the United Kingdom found that the majority of patients prefer their doctors to wear white coats, but the majority of doctors prefer other clothing, such as scrubs. The study found that psychiatrists were among the least likely to wear white coats and when they are worn, they are typically worn over the scrubs. Some medical doctors view the coats as hot and uncomfortable, and many feel that they spread infection.
=== Interactions between biomolecules === Coimmunoprecipitation Electrophoretic mobility shift assay Southwestern blotting Isothermal titration calorimetry Fluorescence anisotropy Microscale thermophoresis
Sources: en.wikipedia.org
=== Metronidazole === Metronidazole is an antibacterial agent that kills bacteria by damaging cellular DNA and hence cellular function. Metronidazole is usually given to people who have diarrhea caused by Clostridioides difficile bacteria. Patients who are taking metronidazole are sometimes advised to avoid alcohol, even after 1 hour following the last dose. Although older data suggested a possible disulfiram-like effect of metronidazole, newer data has challenged this and suggests it does not actually have this effect.
Peukert argued that the very growth of the welfare state under the Weimar Republic ensured the backlash when social problems were not solved was especially severe. Peukert wrote: "Weimar installed the new principle of the social state, in which, on the one hand, the citizen could now claim public assistance in (his/her) social and personal life, while on the other, the state set up the institutional and normative framework, (defining how) a 'normal' life of the citizen of the state could progress...This process, which had already began before the turn of the century, reached its apex in the Weimar Republic and was also thrown into crisis, as the limits of social technology could achieve were reached in every direction". Peukert wrote that after the First World War, the pre-war mood of optimism gave way to disillusionment as German bureaucrats found social problems to be more insolvable than at first thought, which in turn, guided by the prevailing Social Darwinist and eugenicist values led them to place increasing emphasis on saving the biologically "fit" while the biologically "unfit" were to be written off. Peukert used as an example the fact that social workers had before the First World War had believed it was possible to ensure that every child in Germany was brought up in a happy home and by 1922 were instead declaring that certain young people were "biologically" prone to being "unfit", requiring a law on detention that was to remove them from society forever.
=== Bleeding and blood clot risk === Cirrhosis can increase the risk of bleeding. The liver produces various proteins in the coagulation cascade (coagulation factors II, VII, IX, X, V, and VI). When damaged, the liver is impaired in its production of these proteins. This will ultimately increase bleeding as clotting factors are diminished. Clotting function is estimated by lab values, mainly platelet count, prothrombin time (PT), and international normalized ratio (INR). The American Gastroenterological Association (AGA) provided recommendations in 2021 in regards to coagulopathy management of cirrhotic patients in certain scenarios.
=== Food === Fumaric acid has been used as a food acidulant since 1946. It is approved for use as a food additive in the EU, USA, Australia, and New Zealand. As a food additive, it is used as an acidity regulator and can be denoted by the E number E297. It is generally used in beverages and baking powders for which requirements are placed on purity. Fumaric acid is used in the making of wheat tortillas as a food preservative and as the acid in leavening. It is generally used as a substitute for tartaric acid and occasionally in place of citric acid, at a rate of 1 g of fumaric acid to every ~1.5 g of citric acid, in order to add sourness, similarly to the way malic acid is used. As well as being a component of some artificial vinegar flavors, such as "Salt and Vinegar" flavored potato chips, it is also used as a coagulant in stove-top pudding mixes. The European Commission Scientific Committee on Animal Nutrition, part of DG Health, found in 2014 that fumaric acid is "practically non-toxic" but high doses are likely nephrotoxic after long-term use.
Sources: en.wikipedia.org
=== Livestock and crop predation === A limitation of food sources in early spring and wild berry and nut crop failures in summer may contribute to bears regularly feeding from human-based food sources. These bears often eat crops, especially during autumn hyperphagia when natural foods are scarce. Favored crops include apples, oats and corn. American black bears can do extensive damage in areas of the northwestern United States by stripping the bark from trees and feeding on the cambium. Livestock depredations occur mostly in spring. Although they occasionally hunt adult cattle and horses, they seem to prefer smaller prey such as sheep, goats, pigs and young calves. They usually kill by biting the neck and shoulders, though they may break the neck or back of the prey with blows with the paws. Evidence of a bear attack includes claw marks and is often found on the neck, back and shoulders of larger animals. Surplus killing of sheep and goats is common. American black bears have been known to frighten livestock herds over cliffs, causing injuries and death to many animals; whether this is intentional is not known. Occasionally bears kill pets, especially domestic dogs, which are most prone to harass a bear. It is not recommended to use unleashed dogs to deter bear attacks. Although large, aggressive dogs can sometimes cause a bear to run, if pressed, angry bears often turn the tables and end up chasing the dogs in return. A bear in pursuit of a pet dog can threaten both canid and human lives.
Polyphenol oxidase (PPO; also polyphenol oxidase i, chloroplastic), an enzyme involved in fruit browning, is a tetramer that contains four atoms of copper per molecule. PPO may accept monophenols and/or o-diphenols as substrates. The enzyme works by catalyzing the o-hydroxylation of monophenol molecules in which the benzene ring contains a single hydroxyl substituent to o-diphenols (phenol molecules containing two hydroxyl substituents at the 1, 2 positions, with no carbon between). It can also further catalyse the oxidation of o-diphenols to produce o-quinones. PPO catalyses the rapid polymerization of o-quinones to produce black, brown or red pigments (polyphenols) that cause fruit browning. The amino acid tyrosine contains a single phenolic ring that may be oxidised by the action of PPOs to form o-quinone. Hence, PPOs may also be referred to as tyrosinases. Common foods producing the enzyme include mushrooms (Agaricus bisporus), apples (Malus domestica), avocados (Persea americana), banana (Musa (genus)), and lettuce (Lactuca sativa). Fruits high in flavan-3-ols, but low in PPOs (notably berries), are commonly combined with banana in smoothies, resulting in reduced bioavailability of flavan-3-ols and other polyphenols.
In the 1950s and 1960s, the Green Revolution aimed to bring modern Western agricultural techniques (like nitrogen fertilizers and pesticides) to Asia. Investments in agriculture, such as fund fertilizers and seeds, increased food harvests and thus food production. Consequently, food prices and malnutrition decreased (as they had earlier in Western nations).
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.